Hello, welcome to Panjin Tianyuan!

  • 盤錦天源藥業有限公司
  • 盤錦天源藥業有限公司
Copyright: Panjin Tianyuan Pharmaceutical Co., Ltd.  遼ICP備11017563號-1 
powered by  www.300.cn     jinzhou.300.cn
>
>
>
Silymarin or diabetic nephropathy

Silymarin or diabetic nephropathy

Classification:
Industry News
Author:
2018/06/22 15:08
Page view
[Abstract]:
ArecentstudybyFallahzadehetal.intheJournalofAmericanJournalofNephrologyfoundanewpotentialagentforthetreatmentofdiabeticnephropathy:silymarin.Diabeticnephropathyisthemostcommoncauseofdiabeticrenalfailureworldwide.Fallahzadehandhiscolleaguesstudiedanewpotentialagentfortreatingdiabeticnephropathy:theherbalsilymarin,whichhasantioxidantandanti-inflammatoryproperties.Researchersconductedarandomized,double-blind,placebo-controlledclinicaltrialtoassessthepotentialefficacyandsafetyofsilymarin,withtheexceptionoftype2diabetesmellituspatientstreatedwithRASinhibitorsandpatientswithobviousnephropathy.Patientswithsignificantproteinuriaandoliguriawererandomlyassignedtosilymarin.Intheensuingdiscussion,researchersfoundrareopportunitiesandspecialchallengesinusingplantproductstotreatdiseases.Comparedwithtraditionalmedicines,plantsareusuallyamixtureofunknowningredients,andspecialattentionmustbepaidtotheanalysisofallpotentialactiveingredientsandbatch-to-batchchanges.

A recent study by Fallahzadeh et al. in the Journal of American Journal of Nephrology found a new potential agent for the treatment of diabetic nephropathy: silymarin.

Diabetic nephropathy is the most common cause of diabetic renal failure worldwide. Fallahzadeh and his colleagues studied a new potential agent for treating diabetic nephropathy: the herbal silymarin, which has antioxidant and anti-inflammatory properties.

Researchers conducted a randomized, double-blind, placebo-controlled clinical trial to assess the potential efficacy and safety of silymarin, with the exception of type 2 diabetes mellitus patients treated with RAS inhibitors and patients with obvious nephropathy. Patients with significant proteinuria and oliguria were randomly assigned to silymarin. In the ensuing discussion, researchers found rare opportunities and special challenges in using plant products to treat diseases. Compared with traditional medicines, plants are usually a mixture of unknown ingredients, and special attention must be paid to the analysis of all potential active ingredients and batch-to-batch changes.

网球冠军李娜生活照
天津时时彩三星基本走势 非凡炸金花提现版1.1.1 极速赛车软件免费 mg电子游戏手机客户端 后三组选包胆中奖金额 网络赌博龙虎怎么老输 凯撒娱乐会所 重庆快乐十分爱彩乐 11选5任必中方法 时时彩大小单双定位计划 广东时时预测器 时时彩五星组选120规律 百灵百人牛牛经典版 时时彩平刷能赚钱吗 澳门21点规则 鼎隆娱乐怎么样